These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 9413702)

  • 1. Potential role of muscarinic agonists in Alzheimer's disease.
    Avery EE; Baker LD; Asthana S
    Drugs Aging; 1997 Dec; 11(6):450-9. PubMed ID: 9413702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists.
    Fisher A
    Jpn J Pharmacol; 2000 Oct; 84(2):101-12. PubMed ID: 11128032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease.
    Clader JW; Wang Y
    Curr Pharm Des; 2005; 11(26):3353-61. PubMed ID: 16250841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives.
    Fisher A; Michaelson DM; Brandeis R; Haring R; Chapman S; Pittel Z
    Ann N Y Acad Sci; 2000; 920():315-20. PubMed ID: 11193170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.
    Fisher A; Brandeis R; Bar-Ner RH; Kliger-Spatz M; Natan N; Sonego H; Marcovitch I; Pittel Z
    J Mol Neurosci; 2002; 19(1-2):145-53. PubMed ID: 12212772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy.
    Verma S; Kumar A; Tripathi T; Kumar A
    J Pharm Pharmacol; 2018 Aug; 70(8):985-993. PubMed ID: 29663387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Selective M1 muscarinic agonists: failure of therapeutic strategy against Alzheimer's disease or inappropriate tactics?].
    Vamvakidès A
    Ann Pharm Fr; 2003 May; 61(3):207-10. PubMed ID: 12714934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential for muscarinic receptor subtype-specific pharmacotherapy for Alzheimer's disease.
    McKinney M; Coyle JT
    Mayo Clin Proc; 1991 Dec; 66(12):1225-37. PubMed ID: 1749291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of muscarinic agonists in the treatment of Alzheimer's disease.
    Messer WS
    J Mol Neurosci; 2002; 19(1-2):187-93. PubMed ID: 12212779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards a high-affinity allosteric enhancer at muscarinic M1 receptors.
    Lazareno S; Popham A; Birdsall NJ
    J Mol Neurosci; 2002; 19(1-2):123-7. PubMed ID: 12212769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscarinic agonists and antagonists in the treatment of Alzheimer's disease.
    Greenlee W; Clader J; Asberom T; McCombie S; Ford J; Guzik H; Kozlowski J; Li S; Liu C; Lowe D; Vice S; Zhao H; Zhou G; Billard W; Binch H; Crosby R; Duffy R; Lachowicz J; Coffin V; Watkins R; Ruperto V; Strader C; Taylor L; Cox K
    Farmaco; 2001 Apr; 56(4):247-50. PubMed ID: 11421251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscarinic agonists as preventative therapy for Alzheimer's disease.
    Beach TG
    Curr Opin Investig Drugs; 2002 Nov; 3(11):1633-6. PubMed ID: 12476965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muscarinic M(1) agonists in the treatment of Alzheimer's disease.
    Korczyn AD
    Expert Opin Investig Drugs; 2000 Oct; 9(10):2259-67. PubMed ID: 11060805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.
    Fisher A
    Neurotherapeutics; 2008 Jul; 5(3):433-42. PubMed ID: 18625455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies.
    Flynn DD; Ferrari-DiLeo G; Levey AI; Mash DC
    Life Sci; 1995; 56(11-12):869-76. PubMed ID: 10188787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models.
    Chandra JN; Malviya M; Sadashiva CT; Subhash MN; Rangappa KS
    Neurochem Int; 2008 Feb; 52(3):376-83. PubMed ID: 17719699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the physiological relevance of muscarinic acetylcholine receptors in Alzheimer's disease.
    Koch HJ; Haas S; Jürgens T
    Curr Med Chem; 2005; 12(24):2915-21. PubMed ID: 16305479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update.
    Fisher A
    Curr Alzheimer Res; 2007 Dec; 4(5):577-80. PubMed ID: 18220527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscarinic receptors and novel strategies for the treatment of age-related brain disorders.
    Ehlert FJ; Roeske WR; Yamamura HI
    Life Sci; 1994; 55(25-26):2135-45. PubMed ID: 7997072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease.
    Pákáski M; Kálmán J
    Neurochem Int; 2008 Nov; 53(5):103-11. PubMed ID: 18602955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.